The BTK-inhibitor ibrutinib may protect against pulmonary injury in COVID-19 infected patients

[avzuclav]

"Ibrutinib and possibly other BTK-inhibitors may therefore provide protection against lung injury, and even improve pulmonary function in hypoxic patients with COVID-19 as we observed in this series of WM patients on ibrutinib. These findings should be considered as hypothesis generating and preliminary in nature. Patients on ibrutinib, and possibly other BTK-inhibitors may well benefit with continuation of their therapy despite the diagnosis of COVID-19. It will be important to further validate these findings in other patient populations on BTK-inhibitors, including CLL patients. Clinical trials examining the benefit of BTK-inhibitors are being initiated by us and others in COVID-19 patients in pulmonary distress, and the outcome of these prospective, randomized studies will be needed to confirm these preliminary observations. "

Click on the PDF button here:

ashpublications.org/blood/a...

[Justasheet1]

Avz,

Thank you for validating my question about continuing with ibrutinib treatment once infected with the virus.

Very good info.

Thanks,

Jeff

[catnapcrew]

Thanks for sharing this. My specialist said to stop ibrutinib if I got a fever - I’m going to raise this next Telehealth appt.

[catnapcrew in reply to catnapcrew]

Couldn’t wait for appointment so I emailed and forwarded this but still told to stop ibrutinib if I get a fever. I’m on a clinical trial under excellent care - I’d say the best in Australia for cll. Will try to find out why at next appt. maybe someone on here knows??